Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, 730000, China.
Key Laboratory of Evidence-Based Medicine & Knowledge Translation of Gansu Province, Lanzhou, 730000, China.
Future Oncol. 2021 Mar;17(9):1105-1124. doi: 10.2217/fon-2020-0822. Epub 2021 Feb 5.
This study aimed to review the association between antidepressive agent (AD) use and the incidence risk of breast cancer. CBM, WOS, Embase, PubMed and Cochrane Library were systematically searched in July 2019. The methodological quality of the studies was assessed through the Newcastle-Ottawa Scale. We included 19 studies from six countries or regions with relationships between breast cancer and ADs. Subgroup analysis showed no significant association in nested case-control or case-control studies; however, cohort studies revealed a significant association (odds ratio = 1.11; 95% CI: 1.04-1.17). This meta-analysis indicates that breast cancer was not associated with the use of ADs when considering all types of studies, but an association was observed if we considered cohort studies.
本研究旨在回顾抗抑郁药物（AD）使用与乳腺癌发病风险之间的关联。2019 年 7 月，系统检索了 CBM、WOS、Embase、PubMed 和 Cochrane Library。通过 Newcastle-Ottawa 量表评估研究的方法学质量。我们纳入了来自六个国家或地区的 19 项研究，这些研究探讨了乳腺癌与 AD 之间的关系。亚组分析显示，巢式病例对照或病例对照研究中无显著相关性；然而，队列研究显示出显著相关性（比值比=1.11；95%可信区间：1.04-1.17）。本荟萃分析表明，考虑所有类型的研究时，乳腺癌与 AD 使用无关，但如果考虑队列研究，则观察到相关性。
